Xeris Biopharma COO Executes 25,000‑Share Sale Amid 18% Monthly Surge – Insider Plan Raises Questions About Long‑Term Confidence

Insider Selling Continues Amid a Rally – What It Means for Xeris Biopharma Investors

The latest Rule 144 filing from Kevin McCulloch, Xeris Biopharma’s chief operating officer, shows a 25,000‑share holding sale executed on September 28, 2026, at $10.00 per share. The transaction is part of a broader pattern of regular block sales under McCulloch’s 10(b)(5) trading plan, which has seen him divest roughly 30 000 shares between July and September 2026. The most recent sale comes just one day after the stock closed at $9.83, giving the sale a 0.02 % price uplift that aligns with the near‑peak 52‑week high of $10.08.

Why the Timing Matters

Xeris’s share price has surged 18.4 % over the last month, 24.7 % year‑to‑date, and the company has a market cap of about $1.66 billion. With a price‑earnings ratio of –89.22, the stock is trading in a steep discount relative to earnings, reflecting the uncertainty that often accompanies early‑stage biopharma platforms. In this context, a series of insider sales can be a double‑edged sword. On one hand, the consistent use of a pre‑arranged trading plan mitigates the perception of opportunistic “pump‑and‑dump” selling, suggesting that McCulloch is following a disciplined exit strategy rather than reacting to short‑term price swings. On the other hand, frequent large‑block sales can signal that the management team is not fully confident in the company’s near‑term upside, which may dampen long‑term investor sentiment.

Investor Takeaway: Caution or Opportunity?

The 2026‑09‑28 sale, while modest relative to the company’s overall shares outstanding, occurs in a period of high social‑media buzz (682 % communication intensity) and a strongly positive sentiment (+65). The market’s current bullish mood may buffer the impact of insider selling, but it also raises the risk of a short squeeze if the stock continues to climb. For investors, the key question is whether the underlying platform—liquid‑stable injectable formulations—will deliver commercial traction quickly enough to justify the current valuation. The recent insider activity should be viewed as a signal to watch for a potential pullback if the company fails to meet quarterly milestones.

Kevin McCulloch: A Pattern of Planned Exits

McCulloch’s insider history is characterized by a series of block sales under the 10(b)(5) framework, with the largest single sale of 90,000 shares in July 2026 at $8.03 per share. Prior to that, he sold 21,918 shares in August at $8.08, and 15,000 shares in August at $8.02. In March 2026 he purchased 48,894 shares at $4.09, indicating an appetite for accumulating equity when prices are low. This “buy‑low, sell‑high” pattern is consistent with a long‑term view of Xeris’s technology, but also demonstrates a readiness to monetize holdings when the market reaches a critical valuation point. The consistent use of a trading plan gives investors confidence that McCulloch’s transactions are pre‑planned rather than reactive.

Outlook for Xeris Biopharma

The company’s current trajectory—strong share price momentum, high social‑media buzz, and a disciplined insider selling regime—paints a complex picture. If the platform advances toward commercial approvals, the stock could sustain its upward trend, potentially rewarding long‑term holders. Conversely, continued insider exits might presage a reassessment of the company’s prospects, especially if earnings remain elusive. For investors, the prudent approach is to monitor quarterly results, regulatory filings, and any shifts in insider activity, while staying attuned to the broader market sentiment that has amplified both the buzz and the potential volatility of Xeris’s shares.